Cytel expands biostatistics software business in Barcelona, Paris

Cambridge, MA-based biometrics CRO Cytel opened up shop in two European locations this week: Barcelona and Paris. This brings its overall footprint across Europe, the U.S. and India to 800 staff in 10 offices.

Cytel offers clinical research software, and the new locations, particularly the Barcelona office, will enable it to build up its data science arm, according to a release. The expansion in Paris, where it already had an office, will bring together biostatisticians and statistical programmers.

“The development of a dedicated data science group is a natural progression for Cytel, as an established leader in the fields of biostatistics and data analysis,” strategic consulting vice president Yannis Jemiai said. “There is now a wealth of genomic, proteomic, diagnostic and electronic data available with the power to transform healthcare. We will apply our significant statistical know-how to the mission of unlocking its potential.”

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

Founded almost 30 years ago, the company’s clinical trial design and analysis software is used by top pharma companies as an industry standard, as well as by the FDA. Its biggest software products include East, Compass, StatXact and LogXact.


Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.